Anti-VEGF-resistant subretinal fluid is associated with better vision and reduced risk of macular atrophy

BACKGROUND/AIM: To evaluate relationships between subretinal fluid (SRF), macular atrophy (MA) and visual outcomes in ranibizumab-treated neovascular age-related macular degeneration (nAMD). METHODS: This post hoc HARBOR trial (NCT00891735) analysis included ranibizumab-treated (0.5 or 2.0 mg, month...

ver descrição completa

Detalhes bibliográficos
Principais autores: Zarbin, Marco A, Hill, Lauren, Maunz, Andreas, Gliem, Martin, Stoilov, Ivaylo
Formato: Online Atigo Texto
Idioma:English
Publicado em: BMJ Publishing Group 2022
Assuntos:
Clinical Science
Acesso em linha:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606534/
https://www.ncbi.nlm.nih.gov/pubmed/34039560
http://dx.doi.org/10.1136/bjophthalmol-2020-318688

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606534/
https://www.ncbi.nlm.nih.gov/pubmed/34039560
http://dx.doi.org/10.1136/bjophthalmol-2020-318688

Registros relacionados